Hartford Business Journal

HBJ041723

Issue link: https://nebusinessmedia.uberflip.com/i/1496993

Contents of this Issue

Navigation

Page 51 of 55

52 HARTFORDBUSINESS.COM | APRIL 17, 2023 The Lists Largest bioscience & biotechnology companies in Connecticut Ranked by number of employees statewide as of November 2022 Rank Company No. CT employees/ no. worldwide employees Headquarters/ focus Ownership type/ ticker symbol Head of company/ year founded 1 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road, Ridgefield, CT 06877 203-798-9988; boehringer-ingelheim.us 2,600 52,000 Ridgefield Development and manufacturer of human healthcare products especially in the areas of unmet medical need Private Jean-Michel Boers President, CEO & managing director, Boehringer Ingelheim USA 1885 1 Pfizer Inc. 558 Eastern Point Road, Groton, CT 06340 (1) 860-441-4100; .pfizer.com 2,600 78,500 New York, N.Y. Pharmaceutical research, development and manufacturing Public NYSE: PFE Albert Bourla CEO 1849 3 Medtronic Inc. 60 Middletown Ave., North Haven, CT 06473 203-492-5000; medtronic.com 2,500 95,000 Dublin, Ireland Healthcare technology with treatments for 70 health conditions, cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems and more Public NYSE: MDT Geoffrey S. Martha CEO 1949 4 PerkinElmer Inc. 710 Bridgeport Ave., Shelton, CT 06484 (2) 203-925-4600; perkinelmer.com 563 16,700 Waltham, Mass. Detection, imaging, informatics, software and services Public NYSE: PKI Prahlad Singh CEO 1937 5 Alexion Pharmaceuticals Inc. (3) 100 College St., New Haven, CT 06510 475-230-2596; alexion.com 500 (4) 3,800 (4) Boston, Mass. Severe and life-threatening rare disorders Public NASDAQ: AZN Marc Dunoyer CEO, Alexion & CFO, AstraZeneca 1992 5 CooperSurgical Inc. (5) 75 Corporate Drive, Trumbull, CT 06611 203-601-5200; coopersurgical.com 500 (6) 12,000 Trumbull Development and commercialization of medical devices and diagnostics for women's health Public NYSE: COO (7) Holly Sheffield President 1990 7 The Jackson Laboratory for Genomic Medicine 10 Discovery Drive, Farmington, CT 06032 860-837-2474; jax.org 450 3,000 Bar Harbor, Maine Discovery of genomic causes of disease and development of diagnostics and therapeutics Non-profit Charles Lee Scientific director 2014 (8) 8 Arvinas Inc. 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 203-535-1456; arvinas.com 401 401 New Haven Development of therapeutics to treat targets in oncology, immuno-oncology and neuroscience Public NASDAQ: ARVN John Houston President & CEO 2013 9 Sema4 Holdings Corp. (9) 333 Ludlow St., North Tower, 8th Floor, Stamford, CT 06902 800-298-6470; sema4.com 350 (10) 1,100 Stamford Patient-centered health intelligence leveraging AI and machine learning to derive data-driven insights Public NASDAQ: SMFR Katherine Stueland CEO 2017 10 Okay Industries 200 Ellis St., New Britain, CT 06051 860-225-8707; okayind.com 325 450 New Britain Medical device manufacturer Private Jason M. Howey President 1911 11 Hologic Inc. (11) 36 Apple Ridge Road, Danbury, CT 06810 203-207-4500; hologic.com 253 7,000 Marlborough, Mass. Diagnostic, medical imaging and surgical products for women's healthcare Public NASDAQ: HOLX Stephen P. MacMillan Chairman, president & CEO 1986 12 TOMZ Corp. 47 Episcopal Road, Berlin, CT 06037 860-829-0670; tomz.com 230 276 Berlin Medical device manufacturer Private Tom Matulaniec President 1988 13 MannKind Corp. 1 Casper St., Danbury, CT 06810 203-798-8000; mannkindcorp.com 190 (4) 340 (4) Westlake Village, Calif. Development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases Public NASDAQ: MNKD Michael Castagna CEO 1991 14 Arthur G. Russell 750 Clark Ave., Bristol, CT 06010 860-583-4109; arthurgrussell.com 160 N/A Bristol Medical device assembly Private Jason Ensminger President 1945 15 Protein Sciences, a division of Sanofi 1000 Research Parkway, Meriden, CT 06450 203-427-2403; sanofi.com 100 (4) 100,000 (4) Paris, France Vaccine development and protein production Public NASDAQ: SNY (12) Paul Hudson CEO, Sanofi 1994 16 Quantum-Si Inc. 520 Old Whitfield St., Guilford, CT 06437 203-458-7100; quantum-si.com 80 (4) 121 (4) Guilford Life sciences and protein sequencing Public NASDAQ: QSI Jeff Hawkins (13) CEO 2013 17 CARA Therapeutics 107 Elm St., 9th Floor, 4 Stamford Plaza, Stamford, CT 06902 203-406-3700; caratherapeutics.com 53 N/A Stamford Development of therapeutics to treat human diseases associated with pruritus Public NASDAQ: CARA Christopher Posner Director, president & CEO 2004 18 BioSig Technologies Inc. 55 Greens Farms Road, Westport, CT 06880 203-409-5444; biosig.com 49 (4) N/A Westport Bioelectronic medicine Public NASDAQ: BSGM Kenneth L. Londoner CEO 2009 18 BioXcel Therapeutics (14) 555 Long Wharf Drive, New Haven, CT 06511 475-238-6837; bioxceltherapeutics.com 49 180 New Haven Use of artificial intelligence to develop medicines for neuroscience, immuno-oncology and other diseases Public NASDAQ: BTAI Vimal D. Mehta Founder & CEO 2017 20 Precipio Inc. 4 Science Park, 3rd Floor, New Haven, CT 06511 203-787-7888; precipiodx.com 40 (4) 60 (4) Omaha, Neb. Genetic testing Public NASDAQ: PRPO Ilan Danieli CEO 2017 20 Rallybio Corp. 234 Church St., Suite 1020, New Haven, CT 06510 203-859-3820; rallybio.com 40 N/A New Haven Identification and development of transformative therapies for patients with severe and rare disorders Public NASDAQ: RLYB Martin Mackay CEO Stephen Uden COO 2018 Source: Each company via survey as of Nov. 18, 2022, website and/or press releases, annual 10-K reports to SEC and Labor Market Information database, Conn. Dept. of Labor. Note: N/A = Not available. Biohaven Pharmaceutical Holding Co. was acquired as a wholly owned subsidiary by New York's Pfizer Inc. on Oct. 3, 2022, taking only its migraine-related pipeline. All non-migraine research is retained by a new spinoff, Biohaven Ltd., which began public trading on Oct. 4, 2022. The latter remains based in New Haven. (1) Additional clinical research site in New Haven. (2) Additional R&D operation in Branford. (3) A subsidiary of AstraZeneca. (4) Employee figures from 2021 survey. (5) A wholly owned subsidiary of The Cooper Cos. with an additional location in Guilford. (6) Estimate based on labor market research published by the Conn. Dept. of Labor; some market intelligence sites estimate the employee count at 1,600. The Trumbull site is a 214,000-square-foot campus with the main manufacturing facility, product designers, administrative staff and distribution center. (7) For parent company, The Cooper Cos. (8) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (9) Branford location closed Q3 2022 and Stamford laboratory closed Q4 2022; headquarters remains in Stamford. (10) Estimate based on 2021 employee figure of 634 minus office closures and layoff announcements in 2022. (11) Planning to close Danbury location; other sites remain open. (12) For parent company Sanofi S.A. based in Paris, France. (13) Succeeded Jonathan Rothberg in October 2022. (14) In April 2022, created wholly owned subsidiary, OnkosXcel Therapeutics Inc., which will concentrate on oncology. -Compiled by Stephanie R. Meagher LARGEST BIOSCIENCE & BIOTECHNOLOGY COMPANIES IN CONNECTICUT Ranked by number of employees statewide as of November 2022

Articles in this issue

Links on this page

Archives of this issue

view archives of Hartford Business Journal - HBJ041723